
Benzinga Pro data, Protalix BioTherapeutics (AMEX:PLX) reported Q4 sales of $8.55 million. Earnings fell to a loss of $6.67 million, resulting in a 58.78% decrease from last quarter. In Q3, Protalix BioTherapeutics brought in $12.05 million in sales but lost $4.20 million in earnings.